Abstract:Clostridioides difficile is an enteric pathogen that can cause a range of illnesses from mild diarrhea to pseudomembranous colitis and even death. This pathogen often takes advantage of microbial dysbiosis provoked by antibiotic use. With the increasing incidence and severity of infections, coupled with high recurrence rates, there is an urgent need to identify innovative therapies that can preserve the healthy state of the gut microbiota. In this study, we screened a microbial metabolite library against C. difficile. From a collection of 527 metabolites, we identified 18 compounds with no previously identified antimicrobial activity and metabolites that exhibited potent activity against C. difficile growth. Of these 18 hits, five drugs and three metabolites displayed the most potent anti-C. difficile activity and were subsequently assessed against 20 clinical isolates of C. difficile. These potent agents included ecteinascidin 770 (minimum inhibitory concentration against 50% of isolates [MIC50] ≤0.06 µg/mL); 8-hydroxyquinoline derivatives, such as broxyquinoline and choloroquinaldol (MIC50 = 0.125 µg/mL); ionomycin calcium salt, carbadox, and robenidine hydrochloride (MIC50 = 1 µg/mL); and dronedarone and milbemycin oxime (MIC50 = 4 µg/mL). Unlike vancomycin and fidaxomicin, which are the standard-of-care anti-C. difficile antibiotics, most of these metabolites showed robust bactericidal activity within 2-8 h with minimal impact on the growth of representative members of the normal gut microbiota. These results suggest that the drugs and microbial metabolite scaffolds may offer alternative avenues to address unmet needs in C. difficile disease prevention and treatment. Importance: The most frequent infection associated with hospital settings is Clostridioides difficile, which can cause fatal diarrhea and severe colitis, toxic megacolon, sepsis, and leaky gut. Those who have taken antibiotics for other illnesses that affect the gut's healthy microbiota are more susceptible to C. difficile infection (CDI). Recently, some reports showed higher recurrence rates and resistance to anti-C. difficile, which may compromise the efficacy of CDI treatment. Our study is significant because it is anticipated to discover novel microbial metabolites and drugs with microbial origins that are safe for the intestinal flora, effective against C. difficile, and reduce the risk of recurrence associated with CDI.

Clostridioides difficile contamination in the food chain: Detection, prevention and control strategies

The Sources of Bacillus cereus Contamination and their Association with Cereulide Production in Dairy and Cooked Rice Processing Lines

Impacts of Infection with Different Toxigenic Clostridium Difficile Strains on Faecal Microbiota in Children.

Formation and Control of the Viable but Non-culturable State of Foodborne Pathogen Escherichia coli O157:H7

Identification of key taxa that favor intestinal colonization of Clostridium difficile in an adult Chinese population

Comparative genomic and transmission analysis of Clostridioides difficile between environmental, animal, and clinical sources in China

Clostridium difficile in soil conditioners, mulches and garden mixes with evidence of a clonal relationship with historical food and clinical isolates

Clostridium perfringens in the Intestine: Innocent Bystander or Serious Threat?

Clostridioides difficile Infections: Prevention and Treatment Strategies

Molecular Epidemiology and Antimicrobial Susceptibility of Clostridium Difficile Isolated from Hospitals During a 4-Year Period in China.

Molecular Epidemiology of Clostridium Difficile in A Tertiary Hospital of China

Improving culture media for the isolation of Clostridium difficile from compost

Establishment of a Novel Detection Platform for Clostridioides difficile Toxin Genes Based on Orthogonal CRISPR

Exploring novel microbial metabolites and drugs for inhibiting Clostridioides difficile

Probiotics: insights and new opportunities for Clostridioides difficile intervention

Approaches to Controlling Escherichia coli O157:H7, a Foodborne Pathogen and an Emerging Environmental Hazard

Immunization Strategies Against Clostridioides difficile

C. difficile biomarkers, pathogenicity and detection

Diverse Sources and Latent Reservoirs of Community-Associated Clostridioides difficile Infection

Elucidating human gut microbiota interactions that robustly inhibit diverse Clostridioides difficile strains across different nutrient landscapes

Significance of Viable but Nonculturable Escherichia coli: Induction, Detection, and Control.